Clinical Trial

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer

Name: A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer — clinical trial record (NCT07301229)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)

Trial Details

NCT Number	NCT07301229
Lead Sponsor	Shanghai Henlius Biotech
Conditions	Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment	100 participants
Start Date	2025-12-29
Primary Completion	2028-02-21 (estimated)
Study Completion	2028-03-23 (estimated)
Updated on ClinicalTrials.gov	2025-12-24